Stock search

Ticker or company name

Revvity

RVTY · NYSE · Life Sciences Tools & Services

$148,85Down −5,54 (−3,59%)today

Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time

Market cap
$16,6 bn
Div. yield
0,3%
Year to date
+59,6%
52 weeks: $81,22$171,74

Ratio score

56/100
Ratio would watch

based on 9 metrics as of 16.11.2026 ·

Verdict by our methodology based on current metrics. Not an investment recommendation.

Key metrics

4 ✓ · 2 — · 3 ✕ · 1 n/a · hover over a row or tap it to see the trend

All metrics

MetricValue5-year medianIndustry median
P/E TTM68,142,837,9
Forward P/E27,1—29,5
PEG8,0—3,7
P/S5,94,66,6
EV/EBITDA25,820,129,9
P/FCF29,2—38,7
P/B2,41,75,4

Industry median — across 11 profitable companies in “Life Sciences Tools & Services” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.

Price chart

Compare with

Choose a stock

Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.

Analysts

Ratings, 25 analysts

Buy
11
Hold
14
Sell
0

Beat the EPS forecast in 4 of the last 4 quarters

QuarterEstimateActualSurprise
Q3 20261,331,38Up +4,1%
Q2 20261,251,41Up +13,1%
Q1 20261,041,06Up +2,3%
Q4 20251,581,70Up +7,4%

Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.

Financials in charts

MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23
Revenue729 m730 m711 m772 m699 m720 m665 m729 m684 m692 m650 m696 m
EPS0,560,470,360,860,400,460,350,780,770,450,210,65
Margin8,5%7,1%5,7%12,7%6,7%7,5%6,4%13,0%13,8%8,0%4,0%11,3%
FCF152 m181 m95,5 m162 m120 m115 m112 m150 m126 m137 m130 m172 m

From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.

Owners

Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.

Insider trades over 12 months

Over 12 months: no purchases, sales $5,97 m.

NameAmountSharesPrice
gonzales anita1 Oct 2026 · sale$13 06084$155,48
krakowiak maxwell21 Sep 2026 · sale$235 7281 631$144,53
vohra tajinder s16 Sep 2026 · sale$1,03 m7 330$140,88
gonzales anita20 Jul 2026 · sale$9 30685$109,48
gonzales anita20 Apr 2026 · sale$7 42480$92,80
victor miriame24 Feb 2026 · sale$180 8561 862$97,13
mcmurry-heath michelle23 Feb 2026 · sale$58 356600$97,26
singh prahlad r.5 Feb 2026 · sale$109 4911 068$102,52
singh prahlad r.5 Feb 2026 · sale$312 3653 079$101,45
singh prahlad r.5 Feb 2026 · sale$793 4687 885$100,63
singh prahlad r.5 Feb 2026 · sale$1,21 m12 186$99,55
singh prahlad r.5 Feb 2026 · sale$129 4191 307$99,02
goldberg joel s5 Feb 2026 · sale$54 541532$102,52
goldberg joel s5 Feb 2026 · sale$224 6492 217$101,33
goldberg joel s5 Feb 2026 · sale$356 1723 544$100,50

SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.

About the company

Industry
Life Sciences Tools & Services
Exchange
NYSE
Country
US
IPO date
6 Jul 1965

Company description, revenue by segment and region, and the CEO will come later.

Next report
date not announced

An AI summary of the earnings call will come later.

Peers

CompanyPrice
CRLCharles River Laboratories$335,5250would watch403,0−1,2%1,1%
TECHBio-Techne$72,7969would watch62,9+0,9%—
WSTWest Pharmaceutical Services$417,8083would consider45,5+12,6%18,8%
ILMNIllumina, Inc.$198,0075would consider33,6+5,8%19,7%
MTDMettler Toledo$1 727,2663would watch36,5+6,5%22,2%
Compare with peers

Ratio — a score by our methodology, not an investment recommendation.